Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?
Dirk Strumberg(Universitätsklinik Marien Hospital Herne), Brian Schwartz(Cyclacel Pharmaceuticals (United Kingdom)), Ahmad Awada(Centre Hospitalier Interrégional Edith Cavell), Elke Hofstra, D. Voliotis(Bayer (United States)), Jeffrey W. Clark(Massachusetts General Hospital), S. Seeber, O. Christensen(University of Cologne), Andreas Brueckner(Bayer (Germany)), Holger W. Hirte(Hamilton Regional Laboratory Medicine Program), Pr Piccart(Institut Jules Bordet)
Cited by 149
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
|Journal of Clinical Oncology|2012|1.6k